UOC
YARW

UBS O'Connor’s Yarrow Bioscience YARW Stock Holding History

UBS O'Connor’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-911
Closed -$72K – 460
2025
Q1 		$72K Sell
911
-4,005
-81% -$493K ﹤0.01% 271
2024
Q4 		$823K Buy
+4,916
New +$643K 0.02% 246

Other funds holding YARW

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

UBS O'Connor's YARW Position: Q2 2025 in Review

UBS O'Connor sold out of Yarrow Bioscience (YARW) in Q2 2025, closing a stake of 911 shares — an estimated $72K sold.

UBS O'Connor first reported a position in YARW in Q4 2024 and held it in 2 quarters. The position peaked at $823K in Q4 2024. 44 funds tracked by Wall St. Rank hold YARW as of Q2 2025.

  • UBS O'Connor reported no remaining Yarrow Bioscience position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 911 Yarrow Bioscience shares in Q2 2025, an estimated $72K.
  • UBS O'Connor first reported a position in Yarrow Bioscience in Q4 2024 and held it in 2 quarters.
  • UBS O'Connor's Yarrow Bioscience position peaked at $823K in Q4 2024.
  • 44 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.